Compare Celestica Inc (CLS) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

CLS trades at $317.83, up 1.05% today, with strong earnings momentum after beating estimates in Q4 2025, Q1 2026, and Q2 2026. Technical indicators show a bearish trend with support at $309 and resistance at $323. The company reported $12.39B revenue in 2025 with net income of $832.5M, supported by robust cash flow from operations of $659.5M. Recent news highlights a $3B equity offering to fund AI infrastructure growth, though it may cause near-term dilution.

Outlook is positive with analyst consensus price target of $455.33 (43% upside), but risks include equity dilution from the offering and premium valuations (P/E 36.4). Growth catalysts are strong AI-driven demand and expanding partnerships, making CLS a compelling pick for investors seeking exposure to data center infrastructure, albeit with volatility near-term.

DENTSPLY SIRONA (XRAY) trades at $12.12, down 7.97% in 24 hours, with a bearish technical signal and support near $12. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Financials show negative net income margins and ROE, though gross margins remain solid at 49.52%. Recent news highlights institutional stake increases and strategic partnerships, such as the expanded Medline Sinclair relationship in Canada.

The outlook is cautious due to persistent revenue declines and profitability challenges, offset by cost-cutting efforts and digital dentistry growth. Risks include weak European demand and high debt levels, while analyst consensus is Hold with a $11.50 price target, indicating limited near-term upside amid turnaround execution uncertainties.